110 related articles for article (PubMed ID: 2344968)
21. Teniposide (VM-26) in patients with advanced endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group.
Muss HB; Bundy BN; Adcock L
Am J Clin Oncol; 1991 Feb; 14(1):36-7. PubMed ID: 1987736
[TBL] [Abstract][Full Text] [Related]
22. Teniposide in refractory ovarian cancer: a phase II study.
Sessa C; D'Incalci M; Landoni F; Colombo N; Mangioni C
Cancer Treat Rep; 1984 May; 68(5):815-6. PubMed ID: 6722838
[No Abstract] [Full Text] [Related]
23. Treatment of extensive small cell lung cancer with carboplatin and teniposide.
Sørensen BT; Nielsen K; Steenholdt S; Schultz H; Jakobsen A
Eur J Cancer; 1991; 27(9):1109-12. PubMed ID: 1659851
[TBL] [Abstract][Full Text] [Related]
24. Teniposide in advanced breast cancer. A phase II trial in patients with no prior chemotherapy.
Nielsen D; Boas J; Engelholm SA; Hansen OP; Dombernowsky P
Ann Oncol; 1992 May; 3(5):377-8. PubMed ID: 1616891
[TBL] [Abstract][Full Text] [Related]
25. Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC).
Cerny T; Pedrazzini A; Joss RA; Brunner KW
Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1791-4. PubMed ID: 2850194
[TBL] [Abstract][Full Text] [Related]
26. Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Postmus PE; Smit EF; Haaxma-Reiche H; van Zandwijk N; Ardizzoni A; Quoix E; Kirkpatrick A; Sahmoud T; Giaccone G
J Clin Oncol; 1995 Mar; 13(3):660-5. PubMed ID: 7884426
[TBL] [Abstract][Full Text] [Related]
27. High-dose teniposide for refractory malignancies: a phase I study.
de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
[TBL] [Abstract][Full Text] [Related]
28. [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].
Jankowski RP; Vahrson H
Med Klin; 1977 Dec; 72(49):2122-6. PubMed ID: 337083
[TBL] [Abstract][Full Text] [Related]
29. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
Qazi R; Elson P; Khandekar JD
Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
[No Abstract] [Full Text] [Related]
30. The clinical impact of teniposide in the treatment of elderly patients with small-cell lung cancer.
Cascinu S; Del Ferro E; Ligi M; Graziano F; Catalano G
Am J Clin Oncol; 1997 Oct; 20(5):477-8. PubMed ID: 9345331
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of teniposide in adenocarcinoma of the lung.
Sørensen JB; Bach F; Dombernowsky P; Hansen HH
Cancer Chemother Pharmacol; 1991; 27(6):487-9. PubMed ID: 2013120
[TBL] [Abstract][Full Text] [Related]
32. A phase II study with teniposide (VM26) in patients with progressed or relapsed small cell lung cancer (SCLC).
Tummarello D; Guidi F; Di Furia L; Gramazio A; Menichetti E; Cellerino R
J Chemother; 1989 Feb; 1(1):64-7. PubMed ID: 2542470
[TBL] [Abstract][Full Text] [Related]
33. VM26 (NSC-122819): a clinical study in advanced cancer of the lung and ovary.
Samson MK; Baker LH; Talley RW; Fraile RJ
Eur J Cancer (1965); 1978 Dec; 14(12):1395-9. PubMed ID: 216556
[No Abstract] [Full Text] [Related]
34. Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix.
Choi CH; Kim TJ; Lee SJ; Lee JW; Kim BG; Lee JH; Bae DS
Int J Gynecol Cancer; 2006; 16(3):1157-64. PubMed ID: 16803500
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of piperazinedione (NCS 135758) in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Thigpen JT; Blessing J; Homesley HD; Adcock LL
Am J Clin Oncol; 1983 Aug; 6(4):423-6. PubMed ID: 6688150
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Thigpen JT; Ehrlich CE; Conroy J; Blessing JA
Am J Clin Oncol; 1983 Aug; 6(4):427-30. PubMed ID: 6869315
[TBL] [Abstract][Full Text] [Related]
37. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.
Giaccone G; Donadio M; Bonardi G; Testore F; Calciati A
J Clin Oncol; 1988 Aug; 6(8):1264-70. PubMed ID: 2842464
[TBL] [Abstract][Full Text] [Related]
38. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Thigpen T; Shingleton H; Homesley H; Lagasse L; Blessing J
Cancer; 1981 Aug; 48(4):899-903. PubMed ID: 7196794
[TBL] [Abstract][Full Text] [Related]
39. Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial.
Goedhals L; van Wiyk AL; Smith BL; Fourie SJ
Int J Gynecol Cancer; 2006; 16(3):1172-8. PubMed ID: 16803502
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of daily oral teniposide for 20 days.
Smit EF; Splinter TA; Kok TC
Semin Oncol; 1992 Apr; 19(2 Suppl 6):40-2. PubMed ID: 1411637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
